Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
9.32
-0.35 (-3.62%)
At close: Jun 6, 2025, 4:00 PM
9.38
+0.05 (0.59%)
After-hours: Jun 6, 2025, 4:00 PM EDT

Company Description

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.

The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease.

Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.

The company was founded in 2000 and is headquartered in Vancouver, Canada.

Alpha Cognition Inc.
Alpha Cognition logo
Country Canada
Founded 2000
Industry Biotechnology
Sector Healthcare
CEO Michael McFadden

Contact Details

Address:
750 West Pender Street, Suite 1200
Vancouver, BC V6C 2T8
Canada
Phone 604-564-9244
Website alphacognition.com

Stock Details

Ticker Symbol ACOG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001655923
ISIN Number CA02074J5017
SIC Code 2836

Key Executives

Name Position
Michael E. McFadden B.B.A. Chief Executive Officer and Director
Lauren D'Angelo M.B.A. Chief Operating Officer
Kenneth Anthony Cawkell B.A., LL.B. Founder, Consultant, Corporate Secretary and Director
Henry Du CPA Vice President of Finance and Accounting and Interim Chief Financial Officer
Dr. Denis G. Kay Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
May 15, 2025 10-Q Quarterly Report
May 6, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 6, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2025 DEF 14A Other definitive proxy statements
Apr 16, 2025 SCHEDULE 13G Filing
Apr 10, 2025 8-K Current Report
Mar 31, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 14, 2025 SCHEDULE 13G Filing